Physician

Ahmed Ameen Waheed, MD

According to 2025 Medicare claims, Ahmed Waheed, MD (NPI: 1487716346) practices nephrology in the Fort Lauderdale-Pompano Beach-Sunrise, FL market, with the plurality of this provider's patient population coming from Broward, FL. This provider's primary affiliated billing organization is NATIONAL KIDNEY PARTNERS, LLP (NPI: 1780684795; TIN: 593068073) and primary practice location at 33308-4603.

Waheed's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 615 traditional Medicare patients, billed 3,029 HCPCS/CPT codes, and received $245,827 in Medicare payments. The top billing code was 99223 (Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes). Part D data shows 1,300 prescription claims across 258 beneficiaries totaling $285,976 in drug costs, led by Jardiance (Empagliflozin). DME data shows 62 claims. Open Payments data shows 50 records totaling $1,405. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have risen steadily, from $54,858 to $285,976. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	586	2,432	$206,397
2016	682	3,054	$281,859
2017	663	3,031	$285,727
2018	651	2,943	$284,309
2019	625	2,803	$252,593
2020	618	2,974	$272,620
2021	506	2,626	$232,897
2022	591	2,538	$210,551
2023	642	2,834	$242,129
2024	615	3,029	$245,827

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	109	605	$54,858
2016	139	808	$74,425
2017	141	855	$94,777
2018	147	884	$95,528
2019	138	810	$123,417
2020	146	842	$80,831
2021	176	888	$97,310
2022	218	1,078	$139,106
2023	216	1,117	$164,316
2024	258	1,300	$285,976

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	11	$125
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	11	$207
2024	N/R	62	$2,181

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	206	218	$138
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	117	271	$95
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	173	409	$73
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	343	1,218	$63
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	139	219	$13

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Jardiance	Empagliflozin	63	2,430	$47,149
Farxiga	Dapagliflozin Propanediol	26	1,260	$21,956
Kerendia	Finerenone	21	750	$16,641
Veltassa	Patiromer Calcium Sorbitex	13	562	$12,861
Prosol	Parenteral Amino Acid 20% No.1	52	364	$7,316

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J7518	Mycophenolic acid, oral, 180 mg	N	N/R	15	$1,200
J7507	Tacrolimus, immediate release, oral, 1 mg	N	N/R	17	$510
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	15	$282
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	15	$188

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	50	$1,405	Travere Therapeutics, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Ahmed Ameen Waheed, MD?

Tedicare shows public-source Medicare data for Ahmed Ameen Waheed, MD (NPI 1487716346), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Ahmed Ameen Waheed, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Ahmed Ameen Waheed, MD?

Ahmed Ameen Waheed, MD is linked to NATIONAL KIDNEY PARTNERS, LLP (billing NPI 1780684795) in the available physician profile data.

Does Ahmed Ameen Waheed, MD have Open Payments data?

Ahmed Ameen Waheed, MD has 50 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.